Morgan L. McLemore, MD

One star
One star
One star
One star
One half star

Rating: 4.7 out of 5 (132 ratings)

Role

Hematology Oncology
Specialty

Blood Disorders
Research Program

Cell and Molecular Biology
Practicing Since

2001

Call 404-778-1900

Background

Morgan McLemore, MD, has an active basic research laboratory focusing on myeloid differentiation.

Dr. McLemore is a member of the Cancer Genetics and Epigenetics Research Program at Winship Cancer Institute of Emory University. He is also a member of the American Society of Hematology.

Dr. McLemore obtained his medical degree from the University of Texas Health Science Center San Antonio and completed Internal Medicine training at Barnes Hospital (Washington University) in St Louis. He went on to complete a fellowship in Hematology and Oncology at Washington University in St. Louis.

After completing his clinical training, Dr. McLemore pursued research training in the laboratory of Daniel Link studying cytokine receptor signal transduction.

Titles & Roles

Assistant Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine
Director, Adult Sickle Cell Anemia Program

Grady Health System

Education & Training

Education

Residency, Hematology & Oncology, 1994
Barnes - Jewish Hospital
Internship, Internal Medicine, 1993
Barnes - Jewish Hospital
Medical Education, MD, 1990
University of Texas at San Antonio

Board Certifications

Hematology
American Board of Internal Medicine, 1999
Internal Medicine
American Board of Internal Medicine, 1994

Professional Memberships

American Society of Hematology

Research

Publications

Title/Journal	Authors	Publication Date
The Mortality of Adults With Sickle Cell Disease at a Comprehensive Sickle Cell Center. European journal of haematology	JA Afranie-Sakyi, E Randall, R Fasano, ML McLemore, F El Rassi	04/01/2025
Langerhans Cell Histiocytosis With Hypothalamic-pituitary and Bone Involvement: A Report of 2 Cases. JCEM case reports	EA Giraldi, JW Allen, ML McLemore, AG Ioachimescu	03/01/2025
Concerns With Statistical Analysis of 2016 CDC Opioid Guideline and Sickle Cell Outcomes. JAMA internal medicine	AP Patel, M McLemore, VA Sheehan	09/01/2024
Characteristics of Emergency Department Visits Made by Individuals With Sickle Cell Disease in the U.S., 1999-2020. AJPM focus	BK Attell, PM Barrett, BS Pace, ML McLemore, BT McGee, R Oshe, AM DiGirolamo, LL Cohen, AB Snyder	02/01/2024
Adult-onset Langerhans cell histiocytosis of bone: A case series highlighting a rare entity. Annals of diagnostic pathology	T Javadi, C Hill, ML McLemore, S Oskouei, A Bahrami	10/01/2023
Enhanced IgG immune response to COVID-19 vaccination in patients with sickle cell disease. British journal of haematology	H Nakahara, N Cheedarla, HP Verkerke, S Cheedarla, SC Wu, JE Hendrickson, A Chang, ML McLemore, F El Rassi, JD Roback, AS Neish, RM Fasano, SR Stowell	09/01/2023
Evaluating the Discriminatory Ability of the Sickle Cell Data Collection Program's Administrative Claims Case Definition in Identifying Adults With Sickle Cell Disease: Validation Study. JMIR public health and surveillance	A Singh, MK Sontag, M Zhou, M Dasgupta, T Crume, M McLemore, N Galadanci, E Randall, N Steiner, AM Brandow, K Koch, JJ Field, K Hassell, AB Snyder, J Kanter	06/28/2023
Presentations and outcomes among sickle cell disease patients with COVID-19 at a large southern healthcare system. Expert review of hematology	K Clarke, YM Shin, MAK Hall, M Moussa, M McLemore, F El Rassi	02/01/2023
Catastrophic Neurological Complications in 2 Patients With Sickle Cell Disease and COVID-19. Journal of investigative medicine high impact case reports	K Clarke, K Benameur, Z Wiley, YM Shin, M Moussa, F El Rassi, M McLemore	01/01/2022
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. JCO oncology practice	AP Jillella, ML Arellano, M Gaddh, AA Langston, LT Heffner, EF Winton, ML McLemore, C Zhang, CR Caprara, KS Simon, SL Bolds, S DeBragga, P Karkhanis, SH Krishnamurthy, J Tongol, MM El Geneidy, A Pati, JM Gerber, MR Grunwald, J Cortes, A Bashey, RK Stuart, VK Kota	04/01/2021
Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). Blood cells, molecules & diseases	O Niss, RB Lorsbach, M Berger, S Chonat, M McLemore, D Buchbinder, T McCavit, LG Shaffer, J Simpson, JH Schwartz, J Meznarich, M Emberesh, KG Seu, W Zhang, TA Kalfa	03/01/2021
Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients. Transfusion	CL Dean, CL Maier, S Chonat, A Chang, MA Carden, F El Rassi, ML McLemore, SR Stowell, RM Fasano	05/01/2019
Extreme hyperbilirubinemia: An indicator of morbidity and mortality in sickle cell disease. World journal of hepatology	JP Haydek, C Taborda, R Shah, PA Reshamwala, ML McLemore, FE Rassi, S Chawla	03/27/2019
Congenital dyserythropoietic anaemia type I diagnosed in a young adult with a history of splenectomy in childhood for presumed haemolytic anaemia. British journal of haematology	S Chonat, ML McLemore, ST Bunting, S Nortman, K Zhang, TA Kalfa	07/01/2018
Transfusion-transmitted malaria masquerading as sickle cell crisis with multisystem organ failure. Transfusion	CL Maier, PJ Gross, CL Dean, S Chonat, A Ip, M McLemore, F El Rassi, SR Stowell, CD Josephson, RM Fasano	06/01/2018
Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib. Clinical lymphoma, myeloma & leukemia	VK Kota, JH Kong, M Arellano, F El Rassi, M Gaddh, LT Heffner, EF Winton, AP Jillella, ML McLemore, HJ Khoury	12/01/2017
A 49-Year-Old Man With Cirrhosis and Pulmonary Fibrosis. Chest	P Rajaram, B Little, JP Norvell, M McLemore, S Veeraraghavan	02/01/2016
Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma. Leukemia & lymphoma	Z Mitri, MT Siddiqui, F El Rassi, JT Holden, LT Heffner, A Langston, EK Waller, E Winton, M McLemore, L Bernal-Mizrachi, D Jaye, M Arellano, HJ Khoury	07/01/2014
Genistein protects hematopoietic stem cells against G-CSF-induced DNA damage. Cancer prevention research (Philadelphia, Pa.)	LR Souza, E Silva, E Calloway, O Kucuk, M Rossi, ML McLemore	05/01/2014
Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Cancer	AG Antun, S Gleason, M Arellano, AA Langston, ML McLemore, M Gaddh, F el Rassi, L Bernal-Mizrachi, J Galipeau, LT Heffner, EF Winton, HJ Khoury	11/01/2013
G-CSF activation of AKT is not sufficient to prolong neutrophil survival. Journal of leukocyte biology	LR Souza, E Silva, E Calloway, C Cabrera, ML McLemore	06/01/2013
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. British journal of haematology	D Muringampurath-John, DL Jaye, CR Flowers, D Saxe, Z Chen, MJ Lechowicz, DD Weisenburger, M Bast, ML Arellano, L Bernal-Mizrachi, LT Heffner, M McLemore, JL Kaufman, EF Winton, S Lonial, JO Armitage, HJ Khoury	09/01/2012
Managing chronic myeloid leukemia: a coordinated team care perspective. Clinical lymphoma, myeloma & leukemia	S Holloway, K Lord, B Bethelmie-Bryan, MW Shepard, J Neely, M McLemore, SK Reddy, A Montero, WS Jonas, SP Gladney, SL Khanwani, SC Reddy, AK Lahiry, LT Heffner, E Winton, M Arellano, HJ Khoury	04/01/2012
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. Leukemia & lymphoma	D Muringampurath-John, CR Flowers, M Toscano, C Zhengjia, JL Kaufman, M Arellano, L Bernal-Mizrachi, LT Heffner, MJ Lechowicz, M McLemore, E Winton, DL Jaye, S Lonial, HJ Khoury	04/01/2012
High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years. Cancer	M Arellano, E Winton, L Pan, L Lima, M Tighiouart, K Bhalla, LT Heffner, J Neely, D Hutcherson, M McLemore, A Langston, HJ Khoury	01/15/2012
Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia. Clinical lymphoma, myeloma & leukemia	M Arellano, L Bernal-Mizrachi, L Pan, M Tighiouart, L Souza, X Guo, M McLemore, L Lima, S Sunay, LT Heffner, Z Chen, GZ Chen, A Langston, E Winton, HJ Khoury	10/01/2011
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia? Leukemia & lymphoma	LM Lima, K Sampat, S Assouline, D Saxe, S Nault, M Tighiouart, M McLemore, M Arellano, E Winton, L Bernal-Mizrachi, J Cortes, HJ Khoury	06/01/2011
Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer	L Lima, L Bernal-Mizrachi, D Saxe, KP Mann, M Tighiouart, M Arellano, L Heffner, M McLemore, A Langston, E Winton, HJ Khoury	03/15/2011

Awards

Alpha Omega Alpha National Medical Honor Society, 1990
The James R. Eckman Award for Teaching Excellence from the Emory Department of Hematology and Medical Oncology Fellowship Program., 2016
Hidden Gem Award Honoree, in Recognition of Outstanding Contributions to Emory or Beyond, Emory University School of Medicine, 2018

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.7	One star One star One star One star One half star	Provider showed concern
4.7	One star One star One star One star One half star	Provider explained things clearly
4.7	One star One star One star One star One half star	Provider discussed treatment options
4.7	One star One star One star One star One half star	Provider included you in decisions
4.7	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	09/05/2025	very good service
One star One star One star One star Empty star	06/11/2025	In fair to rate as he shows care, listened to my current issues then says well we have to wait on the labsI will call.
One star One star Empty star Empty star Empty star	04/27/2025	Bad; provider ran blood tests already performed which is an extra expense on my part meaning he pays no care to look at my records prior to being seen.
One star One star One star One star One star	10/18/2024	Dr. Mclemore was very thorough, looking at my chart, taking blood (and getting results), before he talked with me.
One star One star One star One star One star	08/11/2024	The physician and staff were very professional and caring.
One star One star One star One star One star	08/09/2024	The Doctor spent time with me and is always very good
One star One star One star One star One star	07/26/2024	He answered my questions.
One star One star One star One star One star	05/24/2024	He was the most knowledgeable doctor I have seen in terms of my disease.
One star One star One star One star One star	05/08/2024	Very good
One star One star One star One star One star	03/27/2024	Most definitely
One star One star One star One star One star	02/07/2024	Top notch interaction!
One star One star One star One star One star	12/01/2023	I thought Dr.McLemore wS just wondetful;very frank and to the point,very informative,very encouraging,very kind and understanding.
One star One star One star One star One star	11/29/2023	I would recommend Dr Macklemore to anyone